Agent/regimen | Histology | ||
Adenoid cystic cancer | Mucoepidermoid cancer | Adenocarcinoma | |
Number of responses/total number of patients (%) | Number of responses/total number of patients (%) | Number of responses/total number of patients (%) | |
Cisplatin[1,2] | 2/32 (6) | 1/5 | 0/5 |
Vinorelbine[3] | 2/13 (15) | - | 2/5 |
Mitoxantrone[4,5] | 5/50 (10) | - | - |
Epirubicin[6] | 2/20 (10) | - | - |
Methotrexate[7] | - | 2/5 (40) | - |
Paclitaxel[8] | 0/14 | 3/14 (21) | 5/17 (29) |
CAP or CAP/FU[7,9-14] | 12/43 (28) | 5/6 (83) | 23/37 (62) |
Cisplatin/anthracycline ± FU[15-18] | 6/19 (32) | 1/4 | 8/14 (57) |
Cyclophosphamide/doxorubicin[7,19] | 2/6 | 0/6 | 1/1 |
Cisplatin/MTX/bleomycin[7,19] | 0/3 | 2/3 (66) | - |
Cisplatin/FU[20] | 0/11 | - | - |
Cisplatin/vinorelbine[3] | 4/9 (44) | - | 1/5 |
Cisplatin/doxorubicin/bleomycin[2] | 3/9 (33) | - | - |
Carboplatin/paclitaxel[21,22] | 2/10 (20) | - | 1/1 |
Cisplatin/gemcitabine[23] | 2/10 (20) | 1/4 (25) | 3/8 (38) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟